ACM
IOVA icon

Atika Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Atika Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-131,500
Closed -$3.94M – 106
2020
Q1 		$3.94M Buy
+131,500
New +$3.49M 0.75% 45
2019
Q3 		– Sell
-185,000
Closed -$4.54M – 82
2019
Q2 		$4.54M Buy
+185,000
New +$2.79M 0.89% 50

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Atika Capital Management's IOVA Position: Q2 2020 in Review

Atika Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2020, closing a stake of 131,500 shares — an estimated $3.94M sold.

Atika Capital Management first reported a position in IOVA in Q2 2019 and held it in 2 quarters. The position peaked at $4.54M in Q2 2019. 257 funds tracked by Wall St. Rank hold IOVA as of Q2 2020.

  • Atika Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • Atika Capital Management sold 131,500 Iovance Biotherapeutics shares in Q2 2020, an estimated $3.94M.
  • Atika Capital Management first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 2 quarters.
  • Atika Capital Management's Iovance Biotherapeutics position peaked at $4.54M in Q2 2019.
  • 257 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2020.

Based on Atika Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.